Pharma Mar (PHM.MC)

Executive Summary

Pharma Mar is a Spanish biopharmaceutical company specializing in marine-derived oncology therapeutics. Its proprietary platform isolates bioactive compounds from ocean organisms, enabling the development of innovative cancer treatments. The company’s portfolio is anchored by Yondelis® (trabectedin), approved for soft tissue sarcoma and ovarian cancer, and includes a clinical-stage pipeline targeting multiple tumor types. With a market capitalization of approximately $1.36 billion, Pharma Mar combines natural product chemistry with synthetic biology to address significant unmet medical needs in oncology. Recent developments highlight the company’s focus on expanding its pipeline and geographic reach. Lurbinectedin (Zepzelca), approved in the US for metastatic small cell lung cancer, is under regulatory review in the EU. Phase 2 studies of PM184, a novel marine-derived compound, are ongoing in solid tumors. The company is also exploring partnerships for Yondelis in emerging markets. With a strong intellectual property portfolio and a unique discovery platform, Pharma Mar is well-positioned for near-term growth, subject to regulatory and clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026EU marketing authorization decision for lurbinectedin in second-line small cell lung cancer70% success
• Q4 2026Phase 2 topline results for PM184 in solid tumors50% success
• Q2 2026Potential licensing deal for Yondelis in China80% success